0

Close
 
Upcoming Allied Market Research
2023
End Stage Renal Disease Market

End Stage Renal Disease Market: Global Opportunity Analysis and Industry Forecast 2023-2030 Market

LS : Medical Devices & Supplies
Report Code: A10199
Nov 2023 | Pages: NA
Tables: NA
Charts: NA

  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.
 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the End Stage Renal Disease Market

Request Now !

End-stage renal diseases are associated with the disorders related to the kidney and take place during chronic kidney disease, which poses an adverse effect on the functioning of the kidney. A patient of end-stage renal disease faces issues in the operation of the kidney and doesn’t work in the ideal way.

The kidney helps in cleaning the wastes and the surplus amount of fluids from the body and is discharged from the body in the forms of urine. The end-stage renal disease patient facing issues in clearing out the waste and it increases the amount of electrolytes, fluids, and other wastes in the body.

End-Stage-Renal-Disease-Market

The patients need to go through kidney transplants or dialysis. Some patients also require conservative care to look over the health and manage the symptoms for providing better health.

COVID-19 scenario analysis:

To take care of the infected population the demand for medical supplies is increasing. Respiratory support devices such as atomizer, life-support machine, oxygen generator, and monitor are among the majorly used medical devices in primary clinical treatment. Moreover, COVID-19 has led to a huge surge in demand for medical supplies such as personal protective equipment including masks, gloves, and protective eyeglasses. With a rise in the number of COVID-19 cases worldwide, the need for medical supplies keeps on rising among, both from healthcare professionals and civil populations for precautionary measures. Manufacturers of these products have a chance to capitalize on this increased demand for medical supplies to ensure adequate and continuous supply of personal protective equipment in the market.
Owing to such factors, COVID 19 is expected to have a significant impact on the End Stage Renal Disease market.

Top impacting factors: Market Scenario Analysis, Trends, Drivers and Impact Analysis:

There has been a significant rise observed in the patients of end-stage renal diseases, chronic kidney diseases, and kidney failures, and an increase in the frequency of diabetes and hypertension are the major factors affecting the growth of the end-stage renal disease market positively. It is also observed that about one-third of the diabetic population are more prone to chronic kidney disease, along with hypertension is occurs due to the rise in the blood pressure, which can further lead to end-stage renal disease. 

Upgrades in the technology used in the treatment for end-stage renal failure are also helping in providing better care and satisfaction along with the better results are propelling the consumption and growth of the end stage renal disease market.

On the other hand, there have been some inconsistencies observed during the functioning of the renal transplant therapies, negative effects on the status in the society and lack of awareness in the population are the major challenges faced in end-stage renal disease.

New product launches and acquisitions to flourish the market:

On October 24th, 2019, Fresenius Medical Care got approval from the FDA to launch their new device which is a breakthrough in the Dialysis System for preventing blood clotting.

On August 14th, 2018, Nephros subsidiary Specialty Renal Products and HemoCleanse Technologies helped in the commercialization of the rights and the development for the regeneration of dialysates and the filtration system which can help in the treatment of renal disease.

Surge in usage in hospitals and clinics segment applications:

Hospitals, dialysis centers, clinics, and research and academic institutes are the major consumers of the end-stage renal disease market. Amongst them, hospitals and clinics are the major end-users of the market.

Key benefits of the report:

  • This study presents the analytical depiction of the global End Stage Renal Disease industry along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the global End Stage Renal Disease market share.
  • The current market is quantitatively analyzed to highlight the global end stage renal disease market growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
  • The report provides a detailed global End Stage Renal Disease market analysis based on competitive intensity and how the competition will take shape in coming years.

Questions answered in the End Stage Renal Disease Market research report:

  • What are the leading market players active in the End Stage Renal Disease market?
  • What the current trends will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities in the market?
  • What are the projections for the future that would help in taking further strategic steps?

 End Stage Renal Disease Market: Global Opportunity Analysis and Industry Forecast 2020–2027 Report Highlights

Aspects Details
By Treatment
  • Transplantation
  • Dialysis
    • Peritoneal Dialysis
    • Hemodialysis
By End User
  • Dialysis Centres
  • Hospital and Clinics
  • Research and Academic Institutes
By Diagnosis
  • Blood tests
  • Urine tests
  • Imaging tests
  • Kidney sample removal for testing
  • Others
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
Key Market Players Keryx Biopharmaceuticals, Inc., Bristol-Myers Squibb Company, Kissei Pharmaceutical Co., Ltd., Novartis AG, Fresenius Medical Care AG and Co. KGaA, Abbott, AstraZeneca, F. Hoffmann La Roche Ltd, Amgen Inc., GlaxoSmithKline PLC
 

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

    • 3.6. COVID-19 Impact Analysis

  • CHAPTER 4: END STAGE RENAL DISEASE MARKET, BY TREATMENT

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Treatment

    • 4.2. Transplantation

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Dialysis

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

      • 4.3.4. Peritoneal Dialysis

        • 4.3.4.1. Market Size and Forecast

      • 4.3.4. Hemodialysis

        • 4.3.4.1. Market Size and Forecast

  • CHAPTER 5: END STAGE RENAL DISEASE MARKET, BY END USER

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By End User

    • 5.2. Dialysis Centres

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Hospital And Clinics

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Research And Academic Institutes

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

  • CHAPTER 6: END STAGE RENAL DISEASE MARKET, BY DIAGNOSIS

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Diagnosis

    • 6.2. Blood Tests

      • 6.2.1. Key Market Trends, Growth Factors and Opportunities

      • 6.2.2. Market Size and Forecast, By Region

      • 6.2.3. Market Share Analysis, By Country

    • 6.3. Urine Tests

      • 6.3.1. Key Market Trends, Growth Factors and Opportunities

      • 6.3.2. Market Size and Forecast, By Region

      • 6.3.3. Market Share Analysis, By Country

    • 6.4. Imaging Tests

      • 6.4.1. Key Market Trends, Growth Factors and Opportunities

      • 6.4.2. Market Size and Forecast, By Region

      • 6.4.3. Market Share Analysis, By Country

    • 6.5. Kidney Sample Removal For Testing

      • 6.5.1. Key Market Trends, Growth Factors and Opportunities

      • 6.5.2. Market Size and Forecast, By Region

      • 6.5.3. Market Share Analysis, By Country

    • 6.6. Others

      • 6.6.1. Key Market Trends, Growth Factors and Opportunities

      • 6.6.2. Market Size and Forecast, By Region

      • 6.6.3. Market Share Analysis, By Country

  • CHAPTER 7: END STAGE RENAL DISEASE MARKET, BY REGION

    • 7.1. Market Overview

      • 7.1.1 Market Size and Forecast, By Region

    • 7.2. North America

      • 7.2.1. Key Market Trends and Opportunities

      • 7.2.2. Market Size and Forecast, By Treatment

      • 7.2.3. Market Size and Forecast, By End User

      • 7.2.4. Market Size and Forecast, By Diagnosis

      • 7.2.5. Market Size and Forecast, By Country

      • 7.2.6. U.S. End Stage Renal Disease Market

        • 7.2.6.1. Market Size and Forecast, By Treatment
        • 7.2.6.2. Market Size and Forecast, By End User
        • 7.2.6.3. Market Size and Forecast, By Diagnosis

      • 7.2.7. Canada End Stage Renal Disease Market

        • 7.2.7.1. Market Size and Forecast, By Treatment
        • 7.2.7.2. Market Size and Forecast, By End User
        • 7.2.7.3. Market Size and Forecast, By Diagnosis

      • 7.2.8. Mexico End Stage Renal Disease Market

        • 7.2.8.1. Market Size and Forecast, By Treatment
        • 7.2.8.2. Market Size and Forecast, By End User
        • 7.2.8.3. Market Size and Forecast, By Diagnosis

    • 7.3. Europe

      • 7.3.1. Key Market Trends and Opportunities

      • 7.3.2. Market Size and Forecast, By Treatment

      • 7.3.3. Market Size and Forecast, By End User

      • 7.3.4. Market Size and Forecast, By Diagnosis

      • 7.3.5. Market Size and Forecast, By Country

      • 7.3.6. France End Stage Renal Disease Market

        • 7.3.6.1. Market Size and Forecast, By Treatment
        • 7.3.6.2. Market Size and Forecast, By End User
        • 7.3.6.3. Market Size and Forecast, By Diagnosis

      • 7.3.7. Germany End Stage Renal Disease Market

        • 7.3.7.1. Market Size and Forecast, By Treatment
        • 7.3.7.2. Market Size and Forecast, By End User
        • 7.3.7.3. Market Size and Forecast, By Diagnosis

      • 7.3.8. Italy End Stage Renal Disease Market

        • 7.3.8.1. Market Size and Forecast, By Treatment
        • 7.3.8.2. Market Size and Forecast, By End User
        • 7.3.8.3. Market Size and Forecast, By Diagnosis

      • 7.3.9. Spain End Stage Renal Disease Market

        • 7.3.9.1. Market Size and Forecast, By Treatment
        • 7.3.9.2. Market Size and Forecast, By End User
        • 7.3.9.3. Market Size and Forecast, By Diagnosis

      • 7.3.10. UK End Stage Renal Disease Market

        • 7.3.10.1. Market Size and Forecast, By Treatment
        • 7.3.10.2. Market Size and Forecast, By End User
        • 7.3.10.3. Market Size and Forecast, By Diagnosis

      • 7.3.11. Russia End Stage Renal Disease Market

        • 7.3.11.1. Market Size and Forecast, By Treatment
        • 7.3.11.2. Market Size and Forecast, By End User
        • 7.3.11.3. Market Size and Forecast, By Diagnosis

      • 7.3.12. Rest Of Europe End Stage Renal Disease Market

        • 7.3.12.1. Market Size and Forecast, By Treatment
        • 7.3.12.2. Market Size and Forecast, By End User
        • 7.3.12.3. Market Size and Forecast, By Diagnosis

    • 7.4. Asia-Pacific

      • 7.4.1. Key Market Trends and Opportunities

      • 7.4.2. Market Size and Forecast, By Treatment

      • 7.4.3. Market Size and Forecast, By End User

      • 7.4.4. Market Size and Forecast, By Diagnosis

      • 7.4.5. Market Size and Forecast, By Country

      • 7.4.6. China End Stage Renal Disease Market

        • 7.4.6.1. Market Size and Forecast, By Treatment
        • 7.4.6.2. Market Size and Forecast, By End User
        • 7.4.6.3. Market Size and Forecast, By Diagnosis

      • 7.4.7. Japan End Stage Renal Disease Market

        • 7.4.7.1. Market Size and Forecast, By Treatment
        • 7.4.7.2. Market Size and Forecast, By End User
        • 7.4.7.3. Market Size and Forecast, By Diagnosis

      • 7.4.8. India End Stage Renal Disease Market

        • 7.4.8.1. Market Size and Forecast, By Treatment
        • 7.4.8.2. Market Size and Forecast, By End User
        • 7.4.8.3. Market Size and Forecast, By Diagnosis

      • 7.4.9. South Korea End Stage Renal Disease Market

        • 7.4.9.1. Market Size and Forecast, By Treatment
        • 7.4.9.2. Market Size and Forecast, By End User
        • 7.4.9.3. Market Size and Forecast, By Diagnosis

      • 7.4.10. Australia End Stage Renal Disease Market

        • 7.4.10.1. Market Size and Forecast, By Treatment
        • 7.4.10.2. Market Size and Forecast, By End User
        • 7.4.10.3. Market Size and Forecast, By Diagnosis

      • 7.4.11. Thailand End Stage Renal Disease Market

        • 7.4.11.1. Market Size and Forecast, By Treatment
        • 7.4.11.2. Market Size and Forecast, By End User
        • 7.4.11.3. Market Size and Forecast, By Diagnosis

      • 7.4.12. Malaysia End Stage Renal Disease Market

        • 7.4.12.1. Market Size and Forecast, By Treatment
        • 7.4.12.2. Market Size and Forecast, By End User
        • 7.4.12.3. Market Size and Forecast, By Diagnosis

      • 7.4.13. Indonesia End Stage Renal Disease Market

        • 7.4.13.1. Market Size and Forecast, By Treatment
        • 7.4.13.2. Market Size and Forecast, By End User
        • 7.4.13.3. Market Size and Forecast, By Diagnosis

      • 7.4.14. Rest of Asia Pacific End Stage Renal Disease Market

        • 7.4.14.1. Market Size and Forecast, By Treatment
        • 7.4.14.2. Market Size and Forecast, By End User
        • 7.4.14.3. Market Size and Forecast, By Diagnosis

    • 7.5. LAMEA

      • 7.5.1. Key Market Trends and Opportunities

      • 7.5.2. Market Size and Forecast, By Treatment

      • 7.5.3. Market Size and Forecast, By End User

      • 7.5.4. Market Size and Forecast, By Diagnosis

      • 7.5.5. Market Size and Forecast, By Country

      • 7.5.6. Brazil End Stage Renal Disease Market

        • 7.5.6.1. Market Size and Forecast, By Treatment
        • 7.5.6.2. Market Size and Forecast, By End User
        • 7.5.6.3. Market Size and Forecast, By Diagnosis

      • 7.5.7. South Africa End Stage Renal Disease Market

        • 7.5.7.1. Market Size and Forecast, By Treatment
        • 7.5.7.2. Market Size and Forecast, By End User
        • 7.5.7.3. Market Size and Forecast, By Diagnosis

      • 7.5.8. Saudi Arabia End Stage Renal Disease Market

        • 7.5.8.1. Market Size and Forecast, By Treatment
        • 7.5.8.2. Market Size and Forecast, By End User
        • 7.5.8.3. Market Size and Forecast, By Diagnosis

      • 7.5.9. UAE End Stage Renal Disease Market

        • 7.5.9.1. Market Size and Forecast, By Treatment
        • 7.5.9.2. Market Size and Forecast, By End User
        • 7.5.9.3. Market Size and Forecast, By Diagnosis

      • 7.5.10. Argentina End Stage Renal Disease Market

        • 7.5.10.1. Market Size and Forecast, By Treatment
        • 7.5.10.2. Market Size and Forecast, By End User
        • 7.5.10.3. Market Size and Forecast, By Diagnosis

      • 7.5.11. Rest of LAMEA End Stage Renal Disease Market

        • 7.5.11.1. Market Size and Forecast, By Treatment
        • 7.5.11.2. Market Size and Forecast, By End User
        • 7.5.11.3. Market Size and Forecast, By Diagnosis

  • CHAPTER 8: COMPETITIVE LANDSCAPE

    • 8.1. Introduction

    • 8.2. Top Winning Strategies

    • 8.3. Product Mapping Of Top 10 Player

    • 8.4. Competitive Dashboard

    • 8.5. Competitive Heatmap

    • 8.6. Top Player Positioning,2022

  • CHAPTER 9: COMPANY PROFILES

    • 9.1. Abbott

      • 9.1.1. Company Overview

      • 9.1.2. Key Executives

      • 9.1.3. Company Snapshot

      • 9.1.4. Operating Business Segments

      • 9.1.5. Product Portfolio

      • 9.1.6. Business Performance

      • 9.1.7. Key Strategic Moves and Developments

    • 9.2. Amgen Inc.

      • 9.2.1. Company Overview

      • 9.2.2. Key Executives

      • 9.2.3. Company Snapshot

      • 9.2.4. Operating Business Segments

      • 9.2.5. Product Portfolio

      • 9.2.6. Business Performance

      • 9.2.7. Key Strategic Moves and Developments

    • 9.3. AstraZeneca

      • 9.3.1. Company Overview

      • 9.3.2. Key Executives

      • 9.3.3. Company Snapshot

      • 9.3.4. Operating Business Segments

      • 9.3.5. Product Portfolio

      • 9.3.6. Business Performance

      • 9.3.7. Key Strategic Moves and Developments

    • 9.4. Bristol-Myers Squibb Company

      • 9.4.1. Company Overview

      • 9.4.2. Key Executives

      • 9.4.3. Company Snapshot

      • 9.4.4. Operating Business Segments

      • 9.4.5. Product Portfolio

      • 9.4.6. Business Performance

      • 9.4.7. Key Strategic Moves and Developments

    • 9.5. F. Hoffmann La Roche Ltd

      • 9.5.1. Company Overview

      • 9.5.2. Key Executives

      • 9.5.3. Company Snapshot

      • 9.5.4. Operating Business Segments

      • 9.5.5. Product Portfolio

      • 9.5.6. Business Performance

      • 9.5.7. Key Strategic Moves and Developments

    • 9.6. Fresenius Medical Care AG And Co. KGaA

      • 9.6.1. Company Overview

      • 9.6.2. Key Executives

      • 9.6.3. Company Snapshot

      • 9.6.4. Operating Business Segments

      • 9.6.5. Product Portfolio

      • 9.6.6. Business Performance

      • 9.6.7. Key Strategic Moves and Developments

    • 9.7. GlaxoSmithKline PLC

      • 9.7.1. Company Overview

      • 9.7.2. Key Executives

      • 9.7.3. Company Snapshot

      • 9.7.4. Operating Business Segments

      • 9.7.5. Product Portfolio

      • 9.7.6. Business Performance

      • 9.7.7. Key Strategic Moves and Developments

    • 9.8. Keryx Biopharmaceuticals, Inc.

      • 9.8.1. Company Overview

      • 9.8.2. Key Executives

      • 9.8.3. Company Snapshot

      • 9.8.4. Operating Business Segments

      • 9.8.5. Product Portfolio

      • 9.8.6. Business Performance

      • 9.8.7. Key Strategic Moves and Developments

    • 9.9. Kissei Pharmaceutical Co., Ltd.

      • 9.9.1. Company Overview

      • 9.9.2. Key Executives

      • 9.9.3. Company Snapshot

      • 9.9.4. Operating Business Segments

      • 9.9.5. Product Portfolio

      • 9.9.6. Business Performance

      • 9.9.7. Key Strategic Moves and Developments

    • 9.10. Novartis AG

      • 9.10.1. Company Overview

      • 9.10.2. Key Executives

      • 9.10.3. Company Snapshot

      • 9.10.4. Operating Business Segments

      • 9.10.5. Product Portfolio

      • 9.10.6. Business Performance

      • 9.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL END STAGE RENAL DISEASE MARKET, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 2. GLOBAL END STAGE RENAL DISEASE MARKET FOR TRANSPLANTATION, BY REGION, 2022-2032 ($MILLION)
  • TABLE 3. GLOBAL END STAGE RENAL DISEASE MARKET FOR DIALYSIS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 4. GLOBAL END STAGE RENAL DISEASE MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 5. GLOBAL END STAGE RENAL DISEASE MARKET FOR DIALYSIS CENTRES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 6. GLOBAL END STAGE RENAL DISEASE MARKET FOR HOSPITAL AND CLINICS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 7. GLOBAL END STAGE RENAL DISEASE MARKET FOR RESEARCH AND ACADEMIC INSTITUTES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 8. GLOBAL END STAGE RENAL DISEASE MARKET, BY DIAGNOSIS, 2022-2032 ($MILLION)
  • TABLE 9. GLOBAL END STAGE RENAL DISEASE MARKET FOR BLOOD TESTS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. GLOBAL END STAGE RENAL DISEASE MARKET FOR URINE TESTS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. GLOBAL END STAGE RENAL DISEASE MARKET FOR IMAGING TESTS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. GLOBAL END STAGE RENAL DISEASE MARKET FOR KIDNEY SAMPLE REMOVAL FOR TESTING, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. GLOBAL END STAGE RENAL DISEASE MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 14. GLOBAL END STAGE RENAL DISEASE MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 15. NORTH AMERICA END STAGE RENAL DISEASE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 16. NORTH AMERICA END STAGE RENAL DISEASE, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 17. NORTH AMERICA END STAGE RENAL DISEASE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 18. NORTH AMERICA END STAGE RENAL DISEASE, BY DIAGNOSIS, 2022-2032 ($MILLION)
  • TABLE 19. U.S. END STAGE RENAL DISEASE, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 20. U.S. END STAGE RENAL DISEASE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 21. U.S. END STAGE RENAL DISEASE, BY DIAGNOSIS, 2022-2032 ($MILLION)
  • TABLE 22. CANADA END STAGE RENAL DISEASE, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 23. CANADA END STAGE RENAL DISEASE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 24. CANADA END STAGE RENAL DISEASE, BY DIAGNOSIS, 2022-2032 ($MILLION)
  • TABLE 25. MEXICO END STAGE RENAL DISEASE, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 26. MEXICO END STAGE RENAL DISEASE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 27. MEXICO END STAGE RENAL DISEASE, BY DIAGNOSIS, 2022-2032 ($MILLION)
  • TABLE 28. EUROPE END STAGE RENAL DISEASE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 29. EUROPE END STAGE RENAL DISEASE, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 30. EUROPE END STAGE RENAL DISEASE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 31. EUROPE END STAGE RENAL DISEASE, BY DIAGNOSIS, 2022-2032 ($MILLION)
  • TABLE 32. FRANCE END STAGE RENAL DISEASE, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 33. FRANCE END STAGE RENAL DISEASE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 34. FRANCE END STAGE RENAL DISEASE, BY DIAGNOSIS, 2022-2032 ($MILLION)
  • TABLE 35. GERMANY END STAGE RENAL DISEASE, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 36. GERMANY END STAGE RENAL DISEASE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 37. GERMANY END STAGE RENAL DISEASE, BY DIAGNOSIS, 2022-2032 ($MILLION)
  • TABLE 38. ITALY END STAGE RENAL DISEASE, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 39. ITALY END STAGE RENAL DISEASE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 40. ITALY END STAGE RENAL DISEASE, BY DIAGNOSIS, 2022-2032 ($MILLION)
  • TABLE 41. SPAIN END STAGE RENAL DISEASE, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 42. SPAIN END STAGE RENAL DISEASE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 43. SPAIN END STAGE RENAL DISEASE, BY DIAGNOSIS, 2022-2032 ($MILLION)
  • TABLE 44. UK END STAGE RENAL DISEASE, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 45. UK END STAGE RENAL DISEASE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 46. UK END STAGE RENAL DISEASE, BY DIAGNOSIS, 2022-2032 ($MILLION)
  • TABLE 47. RUSSIA END STAGE RENAL DISEASE, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 48. RUSSIA END STAGE RENAL DISEASE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 49. RUSSIA END STAGE RENAL DISEASE, BY DIAGNOSIS, 2022-2032 ($MILLION)
  • TABLE 50. REST OF EUROPE END STAGE RENAL DISEASE, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 51. REST OF EUROPE END STAGE RENAL DISEASE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 52. REST OF EUROPE END STAGE RENAL DISEASE, BY DIAGNOSIS, 2022-2032 ($MILLION)
  • TABLE 53. ASIA-PACIFIC END STAGE RENAL DISEASE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 54. ASIA-PACIFIC END STAGE RENAL DISEASE, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 55. ASIA-PACIFIC END STAGE RENAL DISEASE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 56. ASIA-PACIFIC END STAGE RENAL DISEASE, BY DIAGNOSIS, 2022-2032 ($MILLION)
  • TABLE 57. CHINA END STAGE RENAL DISEASE, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 58. CHINA END STAGE RENAL DISEASE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 59. CHINA END STAGE RENAL DISEASE, BY DIAGNOSIS, 2022-2032 ($MILLION)
  • TABLE 60. JAPAN END STAGE RENAL DISEASE, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 61. JAPAN END STAGE RENAL DISEASE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 62. JAPAN END STAGE RENAL DISEASE, BY DIAGNOSIS, 2022-2032 ($MILLION)
  • TABLE 63. INDIA END STAGE RENAL DISEASE, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 64. INDIA END STAGE RENAL DISEASE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 65. INDIA END STAGE RENAL DISEASE, BY DIAGNOSIS, 2022-2032 ($MILLION)
  • TABLE 66. SOUTH KOREA END STAGE RENAL DISEASE, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 67. SOUTH KOREA END STAGE RENAL DISEASE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 68. SOUTH KOREA END STAGE RENAL DISEASE, BY DIAGNOSIS, 2022-2032 ($MILLION)
  • TABLE 69. AUSTRALIA END STAGE RENAL DISEASE, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 70. AUSTRALIA END STAGE RENAL DISEASE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 71. AUSTRALIA END STAGE RENAL DISEASE, BY DIAGNOSIS, 2022-2032 ($MILLION)
  • TABLE 72. THAILAND END STAGE RENAL DISEASE, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 73. THAILAND END STAGE RENAL DISEASE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 74. THAILAND END STAGE RENAL DISEASE, BY DIAGNOSIS, 2022-2032 ($MILLION)
  • TABLE 75. MALAYSIA END STAGE RENAL DISEASE, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 76. MALAYSIA END STAGE RENAL DISEASE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 77. MALAYSIA END STAGE RENAL DISEASE, BY DIAGNOSIS, 2022-2032 ($MILLION)
  • TABLE 78. INDONESIA END STAGE RENAL DISEASE, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 79. INDONESIA END STAGE RENAL DISEASE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 80. INDONESIA END STAGE RENAL DISEASE, BY DIAGNOSIS, 2022-2032 ($MILLION)
  • TABLE 81. REST OF ASIA PACIFIC END STAGE RENAL DISEASE, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 82. REST OF ASIA PACIFIC END STAGE RENAL DISEASE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 83. REST OF ASIA PACIFIC END STAGE RENAL DISEASE, BY DIAGNOSIS, 2022-2032 ($MILLION)
  • TABLE 84. LAMEA END STAGE RENAL DISEASE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 85. LAMEA END STAGE RENAL DISEASE, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 86. LAMEA END STAGE RENAL DISEASE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 87. LAMEA END STAGE RENAL DISEASE, BY DIAGNOSIS, 2022-2032 ($MILLION)
  • TABLE 88. BRAZIL END STAGE RENAL DISEASE, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 89. BRAZIL END STAGE RENAL DISEASE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 90. BRAZIL END STAGE RENAL DISEASE, BY DIAGNOSIS, 2022-2032 ($MILLION)
  • TABLE 91. SOUTH AFRICA END STAGE RENAL DISEASE, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 92. SOUTH AFRICA END STAGE RENAL DISEASE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 93. SOUTH AFRICA END STAGE RENAL DISEASE, BY DIAGNOSIS, 2022-2032 ($MILLION)
  • TABLE 94. SAUDI ARABIA END STAGE RENAL DISEASE, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 95. SAUDI ARABIA END STAGE RENAL DISEASE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 96. SAUDI ARABIA END STAGE RENAL DISEASE, BY DIAGNOSIS, 2022-2032 ($MILLION)
  • TABLE 97. UAE END STAGE RENAL DISEASE, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 98. UAE END STAGE RENAL DISEASE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 99. UAE END STAGE RENAL DISEASE, BY DIAGNOSIS, 2022-2032 ($MILLION)
  • TABLE 100. ARGENTINA END STAGE RENAL DISEASE, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 101. ARGENTINA END STAGE RENAL DISEASE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 102. ARGENTINA END STAGE RENAL DISEASE, BY DIAGNOSIS, 2022-2032 ($MILLION)
  • TABLE 103. REST OF LAMEA END STAGE RENAL DISEASE, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 104. REST OF LAMEA END STAGE RENAL DISEASE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 105. REST OF LAMEA END STAGE RENAL DISEASE, BY DIAGNOSIS, 2022-2032 ($MILLION)
  • TABLE 106. ABBOTT: KEY EXECUTIVES
  • TABLE 107. ABBOTT: COMPANY SNAPSHOT
  • TABLE 108. ABBOTT: OPERATING SEGMENTS
  • TABLE 109. ABBOTT: PRODUCT PORTFOLIO
  • TABLE 110. ABBOTT: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 111. AMGEN INC.: KEY EXECUTIVES
  • TABLE 112. AMGEN INC.: COMPANY SNAPSHOT
  • TABLE 113. AMGEN INC.: OPERATING SEGMENTS
  • TABLE 114. AMGEN INC.: PRODUCT PORTFOLIO
  • TABLE 115. AMGEN INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 116. ASTRAZENECA: KEY EXECUTIVES
  • TABLE 117. ASTRAZENECA: COMPANY SNAPSHOT
  • TABLE 118. ASTRAZENECA: OPERATING SEGMENTS
  • TABLE 119. ASTRAZENECA: PRODUCT PORTFOLIO
  • TABLE 120. ASTRAZENECA: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 121. BRISTOL-MYERS SQUIBB COMPANY: KEY EXECUTIVES
  • TABLE 122. BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT
  • TABLE 123. BRISTOL-MYERS SQUIBB COMPANY: OPERATING SEGMENTS
  • TABLE 124. BRISTOL-MYERS SQUIBB COMPANY: PRODUCT PORTFOLIO
  • TABLE 125. BRISTOL-MYERS SQUIBB COMPANY: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 126. F. HOFFMANN LA ROCHE LTD: KEY EXECUTIVES
  • TABLE 127. F. HOFFMANN LA ROCHE LTD: COMPANY SNAPSHOT
  • TABLE 128. F. HOFFMANN LA ROCHE LTD: OPERATING SEGMENTS
  • TABLE 129. F. HOFFMANN LA ROCHE LTD: PRODUCT PORTFOLIO
  • TABLE 130. F. HOFFMANN LA ROCHE LTD: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 131. FRESENIUS MEDICAL CARE AG AND CO. KGAA: KEY EXECUTIVES
  • TABLE 132. FRESENIUS MEDICAL CARE AG AND CO. KGAA: COMPANY SNAPSHOT
  • TABLE 133. FRESENIUS MEDICAL CARE AG AND CO. KGAA: OPERATING SEGMENTS
  • TABLE 134. FRESENIUS MEDICAL CARE AG AND CO. KGAA: PRODUCT PORTFOLIO
  • TABLE 135. FRESENIUS MEDICAL CARE AG AND CO. KGAA: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 136. GLAXOSMITHKLINE PLC: KEY EXECUTIVES
  • TABLE 137. GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
  • TABLE 138. GLAXOSMITHKLINE PLC: OPERATING SEGMENTS
  • TABLE 139. GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
  • TABLE 140. GLAXOSMITHKLINE PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 141. KERYX BIOPHARMACEUTICALS, INC.: KEY EXECUTIVES
  • TABLE 142. KERYX BIOPHARMACEUTICALS, INC.: COMPANY SNAPSHOT
  • TABLE 143. KERYX BIOPHARMACEUTICALS, INC.: OPERATING SEGMENTS
  • TABLE 144. KERYX BIOPHARMACEUTICALS, INC.: PRODUCT PORTFOLIO
  • TABLE 145. KERYX BIOPHARMACEUTICALS, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 146. KISSEI PHARMACEUTICAL CO., LTD.: KEY EXECUTIVES
  • TABLE 147. KISSEI PHARMACEUTICAL CO., LTD.: COMPANY SNAPSHOT
  • TABLE 148. KISSEI PHARMACEUTICAL CO., LTD.: OPERATING SEGMENTS
  • TABLE 149. KISSEI PHARMACEUTICAL CO., LTD.: PRODUCT PORTFOLIO
  • TABLE 150. KISSEI PHARMACEUTICAL CO., LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 151. NOVARTIS AG: KEY EXECUTIVES
  • TABLE 152. NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 153. NOVARTIS AG: OPERATING SEGMENTS
  • TABLE 154. NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 155. NOVARTIS AG: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL END STAGE RENAL DISEASE MARKET SEGMENTATION
  • FIGURE 2. GLOBAL END STAGE RENAL DISEASE MARKET
  • FIGURE 3. SEGMENTATION END STAGE RENAL DISEASE MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN END STAGE RENAL DISEASE MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALEND STAGE RENAL DISEASE MARKET
  • FIGURE 11. END STAGE RENAL DISEASE MARKET SEGMENTATION, BY BY TREATMENT
  • FIGURE 12. END STAGE RENAL DISEASE MARKET FOR TRANSPLANTATION, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 13. END STAGE RENAL DISEASE MARKET FOR DIALYSIS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 14. END STAGE RENAL DISEASE MARKET SEGMENTATION, BY BY END USER
  • FIGURE 15. END STAGE RENAL DISEASE MARKET FOR DIALYSIS CENTRES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 16. END STAGE RENAL DISEASE MARKET FOR HOSPITAL AND CLINICS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 17. END STAGE RENAL DISEASE MARKET FOR RESEARCH AND ACADEMIC INSTITUTES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 18. END STAGE RENAL DISEASE MARKET SEGMENTATION, BY BY DIAGNOSIS
  • FIGURE 19. END STAGE RENAL DISEASE MARKET FOR BLOOD TESTS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 20. END STAGE RENAL DISEASE MARKET FOR URINE TESTS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 21. END STAGE RENAL DISEASE MARKET FOR IMAGING TESTS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 22. END STAGE RENAL DISEASE MARKET FOR KIDNEY SAMPLE REMOVAL FOR TESTING, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 23. END STAGE RENAL DISEASE MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 24. TOP WINNING STRATEGIES, BY YEAR, 2020-2022*
  • FIGURE 25. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020-2022*
  • FIGURE 26. TOP WINNING STRATEGIES, BY COMPANY, 2020-2022*
  • FIGURE 27. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 28. COMPETITIVE DASHBOARD
  • FIGURE 29. COMPETITIVE HEATMAP: END STAGE RENAL DISEASE MARKET
  • FIGURE 30. Top player positioning, 2022
  • FIGURE 31. ABBOTT: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 32. ABBOTT: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 33. ABBOTT: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 34. AMGEN INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 35. AMGEN INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 36. AMGEN INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 37. ASTRAZENECA: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 38. ASTRAZENECA: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 39. ASTRAZENECA: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 40. BRISTOL-MYERS SQUIBB COMPANY: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 41. BRISTOL-MYERS SQUIBB COMPANY: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 42. BRISTOL-MYERS SQUIBB COMPANY: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 43. F. HOFFMANN LA ROCHE LTD: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 44. F. HOFFMANN LA ROCHE LTD: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 45. F. HOFFMANN LA ROCHE LTD: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 46. FRESENIUS MEDICAL CARE AG AND CO. KGAA: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 47. FRESENIUS MEDICAL CARE AG AND CO. KGAA: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 48. FRESENIUS MEDICAL CARE AG AND CO. KGAA: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 49. GLAXOSMITHKLINE PLC: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 50. GLAXOSMITHKLINE PLC: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 51. GLAXOSMITHKLINE PLC: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 52. KERYX BIOPHARMACEUTICALS, INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 53. KERYX BIOPHARMACEUTICALS, INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 54. KERYX BIOPHARMACEUTICALS, INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 55. KISSEI PHARMACEUTICAL CO., LTD.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 56. KISSEI PHARMACEUTICAL CO., LTD.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 57. KISSEI PHARMACEUTICAL CO., LTD.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 58. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 59. NOVARTIS AG: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 60. NOVARTIS AG: REVENUE SHARE, BY REGION, 2032 (%)

 
 
With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace


With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast


Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts


Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)


Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Enquiry Now
RELATED TAGS

Purchase Full Report of
End Stage Renal Disease Market

Start reading.
This Report and over 68,094+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,690
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Single User
  • $5,820
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Five Users
  • $6,540
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Enterprise
    License/PDF

  • $9,870
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers